PTO/SB/05 (01-04)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to res

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

spond to a conection of inform	ation offices it displays a valid Civib control number.
Attorney Docket No.	9/266
First Inventor	Michael Kenneth CERRETA
Title	Crystalline Phases of a Potent HCV Inhibitor
Express Mail Label No.	EV 315124415 US

APPLICATION ELEMENTS	Mail Stop Patent Application Commissioner for Patents P.O. Box 1450					
See MPEP chapter 600 concerning utility patent application contents.	Alexandria VA 22313-1450					
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. 3. Specification [Total Pages 33] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the invention - Brief Summary of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. Drawing(s) (35 U.S.C. 113) [Total Sheets 7] 5. Oath or Declaration [Total Sheets 7] 5. Oath or Declaration [Total Sheets 1] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	Alexandria VA 22313-1450 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. Paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.					
18. If a CONTINUING APPLICATION, check appropriate box, and suppose specification following the title, or in an Application Data Sheet under 3.	oly the requisite information below and in the first sentence of the					
Specification rollowing the title, or in an Application Data offeet under St	OIN 1.70.					
Continuation Divisional Continua	tion-in-part (CIP) of prior application No.:					
Prior application information: Examiner	Art Unit:					
For CONTINUATION OR DIVISIONAL APPS only; The entire disclosure of the 5b, is considered a part of the disclosure of the accompanying continuation	e prior application, from which an oath or declaration is supplied under Box					
The incorporation can only be relied upon when a portion has been inadvert						
19. CORRESPONI	DENCE ADDRESS					
Customer Number: 28509	OR Correspondence address below					
Name						
Address						
City	State Zip Code					
Country	elephone Fax					
Name (Print/Type) Philip I. Datlow	Registration No. (Attorney/Agent) 41,482					
Signature Audiles	Date March 25, 2004					

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL		Complete if Known				
		Application Number	Not Yet Assigned			
for EV	2004	Filing Date	March 25, 2004			
for FY 2004 Effective 10/01/2003. Patent fees are subject to annual revision.		First Named Inventor	Michael Kenneth CERRETA			
		Examiner Name	Not Yet Assigned			
Applicant claims small entity status	s. See 37 CFR 1.27	Art Unit ·	Not Yet Assigned			
TOTAL AMOUNT OF PAYMENT	(\$) 1340.00	Attorney Docket No.	9/266			
METHOD OF BAYMENT (abo	ek ell that caplu)	EEE C	M CIII ATION (continued)			

1 / Montey Booke, No. 19720							
METHOD OF PAYMENT (check all that apply)			FEE CALCULATION (continued)				
Check Credit card Money Other None			3. ADDITIONAL FEES				
	Order C There	<u>Large</u> l	Entity	Small	Entity		
Deposit A	Account:	Fee	Fee		Fee	Fee Description	
Deposit Account	02-2955	Code			(\$)	·	Fee Paid
Number		1051	130	2051		Surcharge - late filing fee or oath	
Deposit Account	Boehringer Ingelheim Corporation	1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
Name	authorized to: (check all that apply)	1053	130	1053	130	Non-English specification	
	s) indicated below Credit any overpayments	1812	2,520	1812	2,520	For filing a request for ex parte reexamination	L
	additional fee(s) or any underpayment of fee(s)	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
	s) indicated below, except for the filing fee	1005	4 0401	1005	4 040*	Requesting publication of SIR after	
	entified deposit account.	1805	1,840*	1605	1,040	Examiner action	ļ
	FEE CALCULATION	1251	110	2251	55	Extension for reply within first month	
1. BASIC FI		1252	420	2252	210	Extension for reply within second month	<u> </u>
Large Entity S		1253	950	2253	475	Extension for reply within third month	<u> </u>
	Fee Fee Fee Description Fee Paid	1254	1,480	2254	740	Extension for reply within fourth month	
	Code (\$) 2001 385 Utility filing fee	1255	2,010	2255	1,005	Extension for reply within fifth month	
	2001 385 Utility liling fee 770.00	1401	330	2401	165	Notice of Appeal	
	2003 265 Plant filing fee	1402	330	2402	165	Filing a brief in support of an appeal	
l l	2004 385 Reissue filing fee	1403	290	2403	145	Request for oral hearing	
	2005 80 Provisional filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
	SUBTOTAL (1) (\$) 770.00	1452	110	2452	55	Petition to revive - unavoidable	
		1453	1,330	2453	665	Petition to revive - unintentional	
2. EXTRA C	LAIM FEES FOR UTILITY AND REISSUE	1501	1,330	2501	665	Utility issue fee (or reissue)	
	Extra Claims below Fee Paid	1502	480	2502	240	Design issue fee	
Total Claims Independent	26 -20** = 6 × 18.00 = 108.00	1503	640	2503	320	Plant issue fee	
Claims	5 - 3** = 2 × 86.00 = 172.00	1.460	130	1460	130	Petitions to the Commissioner	
Multiple Deper	290.00 = 290.00	1807	50	1807	7 50	Processing fee under 37 CFR 1.17(q)	
Large Entity		1806	180	1806		Submission of Information Disclosure Stmt	
Fee Fee Code (\$)	Fee Fee <u>Fee Description</u> Code (\$)	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18	2202 9 Claims in excess of 20	1809	770	2809	385	Filing a submission after final rejection	
1201 86	2201 43 Independent claims in excess of 3	,,,,,				(37 CFR 1.129(a))	
1203 290	2203 145 Multiple dependent claim, if not paid	1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1204 86	2204 43 ** Reissue independent claims over original patent	1801	770	2801	385	Request for Continued Examination (RCE)	
1205 18	2205 9 ** Reissue claims in excess of 20 and over original patent	1802	900	1802	900	Request for expedited examination of a design application	
	F70 00	Other	fee (sp	ecify) _			
**or number	previously paid, if greater, For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)					
						11 /	
SUBMITTED F	(*					(Complete (if applicable))	

SUBMITTED BY		(Complete (if applicable))			
Name (Print/Type)	Philip I. Datlow	Registration No. (Attorney/Agent)	41,482	Telephone	203-798-4542
Signature	Milla			Date	March 25, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

APPLICANT(S):

Michael K. CERRETA, et al.

SERIAL NO.:

Not Yet Assigned

CONFIRMATION NO.:

Not Yet Assigned

FILING DATE:

March 25, 2004

DOCKET NO.:

9/266

TITLE:

Crystalline Phases of a Potent HCV Inhibitor

- 1. Patent Application Transmittal (1pg);
- 2. Fee Transmittal FY2004 (1pg, In Triplicate);
- 3. Certificate of Express Mailing (1pg);
- 4. Application Data Sheet (3pgs);
- 5. Specification (33 pgs);
- 6. Drawings (7pgs)

Date Mailed: March 25, 2004

Express Mail Label No. EV 315124415 US

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT 06877-0368

Tel: (203) 798-4542 Date: March 25, 2004 "EXPRESS MAIL" LABEL NO.: EV 315124415 US DEPOSIT DATE: March 22, 2004 25, 2004

I HEREBY CERTIFY THAT THE ABOVE PAPERS AND FEE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:

Commissioner for Patents Mail Stop Patent Application P. O. Box 1450 Alexandria, VA 22313-1450

Philip Datlow Reg. No. 41,482